Bieche We, Parfait B, Tozlu S, Lidereau R, Vidaud Yards: Quantitation regarding androgen receptor gene phrase into the sporadic breast cancers by the real-big date RT-PCR: proof one MYC is an AR-controlled gene. Carcinogenesis. 2001, twenty two (9): 1521-1526. /carcin/twenty-two.nine.1521.
Bratthauer GL, Lininger RA, Child YG, Tavassoli FA: Androgen and estrogen receptor mRNA reputation for the apocrine carcinomas. Diagn Mol Pathol. 2002, 11 (2): 113-118. 9606-200206000-00008.
Gatalica Z: Immunohistochemical data of apocrine breast sores. Uniform more than-expression from androgen receptor with the increasing loss of estrogen and you can progesterone receptors in the apocrine metaplasia and you can apocrine carcinoma in situ. Pathol Res Pract. 1997, 193 (11-12): 753-758.
Have always been J Clin Pathol
Soreide JA, Lea OA, Varhaug JE, Skarstein A, Kvinnsland S: Androgen receptors when you look at the operable cancer of the breast: regards to most other steroid hormone receptors, correlations so you’re able to prognostic circumstances and you can predictive really worth having effectation of adjuvant tamoxifen cures. Eur J Surg Oncol. 1992, 18 (2): 112-118.
Bayer-Garner IB, Smoller B: Androgen receptors: a great marker to boost susceptibility having determining cancer of the breast for the body metastasis off unknown pri, 13 (2): 119-122. /modpathol.3880021.
Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM: Matrix metalloproteinases: biologic pastime and you will logical implications. J Clin Oncol. 2000, 18 (5): 1135-1149.
Pang ST, Flores-Morales A good, Skoog L, Chuan YC, Nordstedt G, Pousette A good: Control away from matrix metalloproteinase 13 term by androgen for the prostate malignant tumors. Oncol Representative. 2004, 11 (6): 1187-1192.
Bryan RM, Mercer RJ, Bennett RC, Rennie GC, Lie TH, Morgan FJ: Androgen receptors in breast cancer. Cancer. 1984, 54 (11): 2436-2440. -0142(19841201)<2436::AID-CNCR2820541121>3.0.
Schippinger W, Regitnig P, Dandachi N, Wernecke KD, Bauernhofer T, Samonigg H, Moinfar F: Investigations of your own prognostic importance of androgen receptor phrase for the metastatic cancer of the breast. Virchows Arc. 2006, 449 (1): 24-30. /s00428-006-0213-6.
Parker RL, Hunter DG, Lesack DW, Cupples JB, Offer DR, Akbari Yards, Gilks CB: Assessment from interlaboratory adaptation on the immunohistochemical dedication of estrogen receptor updates having fun with a breast cancer tissues microarray. 2002, 117 (5): 723-728. /PEF8-GL6F-YWMC-AG56.
Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, , Garcia-Muniz JL: Study of matrix metalloproteinases in addition to their inhibitors when you look at the cancer of the breast. Br J Cancer. 2007, 96 (6): 903-911. /sj.bjc.6603666.
Narita D, Raica M, Suciu C, Cimpean A great, Anghel A beneficial: Immunohistochemical phrase away from androgen receptor and prostate-certain antigen in cancer of the breast. Folia Histochem Cytobiol. 2006, 44 (3): 165-172.
Egeblad meetme giriÅŸ Yards, Werb Z: The properties towards the matrix metalloproteinases within the cancer development. Nat Rev Malignant tumors. 2002, 2 (3): 161-174. /nrc745.
Turk V, Kos J, Turk B: Cysteine cathepsins (proteases)–towards main phase of cancer?. Disease Telephone. 2004, 5 (5): 409-410. /S1535-6108(04)00117-5.
Manes S, Llorente Meters, Lacalle RA, Gomez-Mouton C, Kremer L, Mira Elizabeth, Martinez Air-conditioning: The fresh matrix metalloproteinase-nine handles the fresh new insulin-such gains basis-caused autocrine effect for the DU-145 carcinoma tissues. J Biol Chem. 1999, 274 (11): 6935-6945. /jbc..
Noe V, Fingleton B, Jacobs K, Crawford HC, Vermeulen S, Steelant W, Bruyneel E, Matrisian LM, Mareel Yards: Release of an attack promoter E-cadherin fragment by the matrilysin and you will stromelysin-step 1. J Mobile Sci. 2001, 114 (Pt step one): 111-118.
Fingleton B, Vargo-Gogola T, Crawford HC, Matrisian LM: Matrilysin [MMP-7] phrase picks to have structure with just minimal awareness in order to apoptosis. Neoplasia. 2001, step three (6): 459-468. /sj.neo.7900190.
CO;2-H
Stetler-Stevenson WG: Matrix metalloproteinases within the angiogenesis: a moving address having therapeutic input. J Clin Invest. 1999, 103 (9): 1237-1241. /JCI6870.
Cornelius La, Nehring LC, Harding Age, Bolanowski M, Welgus HG, Kobayashi DK, Penetrate RA, Shapiro SD: Matrix metalloproteinases build angiostatin: outcomes on neovascularization. J Immunol. 1998, 161 (12): 6845-6852.
Jiang Y, Goldberg ID, Shi YE: Advanced positions off cells inhibitors out of metalloproteinases during the malignant tumors. Oncogene. 2002, 21 (14): 2245-2252. /sj.onc.1205291.